OXFORD, United Kingdom — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 16-20, 2023, in Los Angeles, and the International Society for Extracellular Vesicles (ISEV) Annual...
Latest News
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy (SMA). The approval has been granted based on data from two pivotal studies evaluating Evrysdi in infants and adults living with...
NEWBURYPORT — Colton Fontaine was the picture of good health. A standout athlete during his days at Newburyport High, Fontaine went on to enjoy a successful college baseball career at Salem State and now serves as the program’s top assistant coach. But that all changed in the blink of an...
MADISON, Wis. — Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva...
PHILADELPHIA – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia,...
ALAMEDA, Calif. – Exelixis, Inc. today announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior...
In men undergoing active surveillance as an alternative to immediate treatment for prostate cancer, a supervised exercise program can reduce anxiety and fear of cancer progression, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer. “In...
CHICAGO & CAMBRIDGE, Mass. – Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately. “Exicure’s proprietary SNA platform technology holds great potential for treating...
CHICAGO & CAMBRIDGE, Mass. – Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors. “We are pleased to welcome Betsy and Andrew to...
CAMBRIDGE & NOTTINGHAM, England – Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407. These data demonstrate the safety and tolerability of EXN407, as well as clear indications of...